Circadian variation in plasma levels of free-form tissue factor pathway inhibitor antigen in patients with coronary spastic angina.
Tissue factor pathway inhibitor (TFPI) is known to inhibit the initial reaction in the tissue factor-mediated coagulation pathway. We measured plasma free-form TFPI antigen levels and monitored 24-h Holter recordings at 06.00, 14.00 and 22.00 h in 15 patients with coronary spastic angina, 13 patients with stable exertional angina, and 11 control subjects. There was a significant circadian variation in plasma free-form TFPI antigen levels in patients with coronary spastic angina (25.8+/-2.0 ng/ml at 06.00 h, 21.1+/-1.6 ng/ml at 14.00 h, and 20.2+/-1.4 ng/ml at 22.00 h; p<0.01). Furthermore, free-form TFPI antigen levels at 06.00 h were significantly higher in coronary spastic angina patients than in patients with stable exertional angina or control subjects (p<0.01). Free-form TFPI antigen levels increased after the ischemic attacks in coronary spastic angina (p<0.01). This circadian variation correlated with the frequency of attacks, with the peak level occurring between midnight to early morning in patients with coronary spastic angina.
Misumi
K
K
Division of Cardiology, Kumamoto University School of Medicine, Kumamoto City, Japan.
Ogawa
H
H
Yasue
H
H
Soejima
H
H
Suefuji
H
H
Nishiyama
K
K
Takazoe
K
K
Kugiyama
K
K
Tsuji
I
I
Kumeda
K
K
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology; D000789:Angina, Unstable / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D006328:Cardiac Catheterization; D002940:Circadian Rhythm; D017023:Coronary Angiography; D003329:Coronary Vasospasm / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000378:metabolism*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D012307:Risk Factors; D012636:Secretory Rate
D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor